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Heterogeneous Manifestations of Posttransplant Lymphoma in Renal
Transplant Recipients: A Case Series
Rujuta Patila, Rohini Prasharb, and Anita Patelb*
a
Wayne State University School of Medicine, Detroit, Michigan; and bKidney and Pancreas Transplant Program, Henry Ford Transplant
Institute, Detroit, Michigan

ABSTRACT
Posttransplant lymphoproliferative disorder (PTLD) occurs in 1% to 3% of adult renal transplant
recipients (RTRs). PTLD has a heterogeneous presentation and is often associated with EpsteinBarr virus (EBV) and immunosuppression. We present a descriptive case series of 16 RTRs who
demonstrate a variety of PTLD manifestations.
Fifty-six percent received rabbit antithymocyte globulin induction, and 37.5% received basiliximab. Maintenance immunosuppression included glucocorticoids, tacrolimus, and mycophenolate
mofetil. Median time from transplantation to PTLD diagnosis was 96.5 months. PTLD involved
a single site in 44% of RTRs and multiple sites in 56%. PTLD was localized to the gastrointestinal tract in 9 RTRs, in lymph nodes in 9, central nervous system in 4, bone marrow in 3, skin in
3, lungs in 2, perinephric space in 2, mediastinum in 1, and native kidney in 1. PTLD was EBV
positive in 8 RTRs, monomorphic/monoclonal in 14, and of B-cell lineage in 13. Three RTRs
had T-cell PTLD. Immunosuppressive agents, except glucocorticoids, were discontinued at diagnosis. Treatment was chemotherapy either alone (in 14 RTRs) or in combination with radiation.
Complete remission was achieved in 62.5% of RTRs. Renal dysfunction developed in 62.5% of
RTRs, and 4 received dialysis. The overall mortality rate was 62.5%, with median time of death
6.5 months after diagnosis.
PTLD that was EBV negative and had T-cell involvement presented with aggressive disease and
a higher mortality. Clinicians should be aware of the various PTLD manifestations. Early diagnosis and a multidisciplinary approach to treatment is crucial for improved patient outcomes.

P

OSTTRANSPLANT lymphoproliferative disorder (PTLD)
is a serious complication observed after solid organ transplantation. PTLD presents in 1% to 3% of renal transplant
recipients (RTRs) [1,2], contributing signiﬁcantly to the morbidity and mortality (30%-60%) of these patients [1]. PTLD
development is associated with the Epstein-Barr virus (EBV),
although not exclusively, and immunosuppression. Generally,
the pathogenesis of PTLD is related to uncontrolled proliferation of EBV-infected B lymphocytes in the setting of deﬁcient
T-cell cytotoxicity [3,4]. Other risk factors for PTLD development include younger age (<20 years), rabbit antithymocyte
globulin (rATG) induction [5], and viral coinfections like hepatitis C virus [6] and cytomegalovirus (CMV) [7].
PTLD encompasses a group of diseases that range from
benign, self-limiting lymphoproliferation to widely disseminated, aggressive lymphoma. The World Health Organization
characterizes PTLD into 4 categories: early lesions,
© 2021 Elsevier Inc. All rights reserved.
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polymorphic lesions, monomorphic lesions, and classic Hodgkin lymphoma lesions [8]. PTLD is usually of B-cell origin;
however, T-cell origin, including gamma-delta T-cell lymphoma (GDTCL) and natural killer T-cell lymphoma, has also
been described [9]. PTLD localizes commonly to the digestive
tract and the nervous system but can involve any site, such as
lungs [1,10] and skin [11]. Treatment of PTLD always consists
of maintenance immunosuppression reduction and often
involves additional immunochemotherapy regimens, usually
centered around rituximab [12]. However, there has yet to be a
clear consensus on management.
The aim of this study is to describe PTLD based on EBV status, histologic subgroups, localization, and clinical outcomes in
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adult RTRs. We present 16 adult RTRs to demonstrate the clinicopathologic characteristics and outcomes of PTLD in a single
transplant center.

MATERIALS AND METHODS
This is a descriptive study that involved retrospective data collection of
16 adult RTRs diagnosed with PTLD between 2009 and 2020. All
patients received transplants and were followed up at our center, Henry
Ford Hospital in Detroit, Michigan. The analysis included assessment
of demographics, EBV/CMV serology, time from transplantation to
PTLD diagnosis, immunosuppression (induction, maintenance, and
postdiagnosis), PTLD localization and histologic diagnosis, development of renal insufﬁciency (estimated glomerular ﬁltration rate [eGFR]
was calculated using the Modiﬁcation of Diet in Renal Disease equation, 4 (MDRD-4) equation), treatment instituted, and patient and graft
survival. This research did not receive any speciﬁc grant from funding
agencies in the public, commercial, or not-for-proﬁt sectors.

RESULTS
Demographics

Fifty percent (8) of the patients were white, 37.5% (6) were
African American, and 12.5% (2) were Hispanic. Ten (62.5%)
patients received a deceased donor kidney transplant and 6
(37.5%) a living donor kidney transplant (3 unrelated, 3
related). Two patients underwent a dual-organ transplant; 1
received a simultaneous liver-kidney transplant, and the other
received a simultaneous pancreas-kidney transplant. Nine
(56.0%) patients received rATG induction, and 6 (37.5%)

received basiliximab; 1 patient received both basiliximab and
rATG induction. Standard maintenance immunosuppression
received before the PTLD diagnosis for 7 patients was tacrolimus (FK) and mycophenolate mofetil (MMF). Four other
patients received glucocorticoid (GC), FK, and MMF; 1 patient
was switched to GC and everolimus after diagnosis of renal cell
carcinoma. The remaining patients received GC in combination
with either MMF, FK, azathioprine, FK plus sirolimus, or FK
plus azathioprine (Table 1).

Clinical and Pathologic Features

Patients presented with nausea, vomiting, diarrhea, abdominal
pain, B symptoms, and neurologic deﬁcits. The median time
from transplantation to PTLD diagnosis was 96.5 months (<12248 months). At diagnosis, 56% (9) of patients were aged
<60 years, and 44% (7) were aged >60 years. Thirty-one percent
were EBV mismatched, and 12.5% were CMV mismatched;
there were 5 patients with missing EBV serology data (Table 1).
PTLD involved a single site in 44% (7) of patients and multiple sites in 56% (9). In 9 patients (56%), PTLD localized to the
gastrointestinal tract: small bowel in 4 patients, liver in 3, spleen
in 1, and colon in 1. PTLD also localized to the lymph nodes in
56% (9) of patients: mesenteric in 4 patients, retroperitoneal in
2, liver in 1, mediastinal in 1, cervical neck in 1, and in lymph
nodes all throughout the chest, abdomen, and pelvis in 1 patient.
Other PTLD localizations involved the central nervous system
(CNS) (4 patients), bone marrow (3), lungs (2), mediastinum
(1), skin (3), native kidney (1), and perinephric space (2). Seven

Table 1. Baseline Characteristics of Patients
Date of
Transplant
(mo/y)

Type of
Transplant

Induction
Immunosuppression

rATG
rATG
Basiliximab
rATG
Basiliximab
rATG
Basiliximab
rATG
rATG
rATG
rATG
Basiliximab
rATG
Basiliximab
Basiliximab
Basiliximab
rATG

Patient

Sex

Race

Age at
Transplant
(y)

1
2
3
4
5

M
F
M
F
M

W
W
H
W
A

58
57
56
28
55

6/2001
8/2010
2/2008
9/2001
7/2001

LURKT
DDKT
LRKT
LRKT
DDKT

6
7
8
9
10
11
12
13
14
15
16

F
F
M
F
F
M
F
F
M
M
M

W
A
A
H
W
W
A
A
W
W
A

38
35
35
54
64
66
55
70
67
53
36

9/2017
12/2010
8/1998
7/2016
9/2011
3/2016
6/2007
2/2002
4/2014
12/2014
3/2010

LURKT
SPK
LRKT
SLK
DDKT
LURKT
DDKT
DDKT
DDKT
DDKT
DDKT

Maintenance
Immunosuppression
Before Diagnosis

EBV Serology
Donor IgG +/−
Recipient IgG +/−

CMV Serology
Donor IgG +/−
Recipient IgG +/−

GC + AZA
FK + MMF
GC + FK
FK + MMF
GC + FK + SIR

+/−
+/−
*/−
*
*

+/−
−/−
−/+
−/−
+/+

GC + FK + MMF
GC + FK + AZA
GC + MMF
GC + FK + MMF
FK + MMF
GC + FK + MMF
FK + MMF
FK + MMF
FK + MMF
FK + MMF
GC + FK + MMF !
GC + EVLy

+/−
+/+
*/+
+/+
−/+
+/+
+/−
*/+
+/+
+/−
+/+

−/−
+/+
−/+
+/+
−/+
+/−
+/+
−/+
+/+
−/+
−/−

A, African American; AZA, azathioprine; CMV, cytomegalovirus; DDKT, deceased donor kidney transplant; EBV, Epstein-Barr virus; EVL, everolimus; F, female; FK,
tacrolimus; GC, glucocorticoids; H, Hispanic; IgG, immunoglobulin; LRKT, living related kidney transplant; LURKT, living unrelated donor kidney transplant; M, male;
MMF, mycophenolate mofetil; rATG, rabbit antithymocyte globulin; SIR, sirolimus; SLK, simultaneous liver and kidney transplant; SPK, simultaneous pancreas and kidney transplant; W, white.
* Unknown variable.
y
Patient developed renal cell carcinoma in 2016 before posttransplant lymphoproliferative disorder diagnosis, and maintenance immunosuppression was adjusted to
GC + EVL.
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Table 2. Diagnosis and Characteristics of PTLD
Patient

Date of PTLD
Diagnosis (mo/y)

Time from Tx to
PTLD Diagnosis (mo)

1

11/2009

101

2
3

11/2011
8/2016

15
102

4
5

10/2018
3/2013

205
140

6
7
8
9

7/2018
1/2019
4/2019
3/2018

10
97
248
20

10

9/2019

96

11

3/2017

12

12
13
14
15

11/2019
2/2020
6/2017
3/2016

149
215
38
16

16

11/2017

92

PTLD EBV
Status

PTLD Location

Histopathologic Diagnosis

Bone marrow, SB, LN in mesentery
and liver
Perinephric space
CNS, perinephric space,
retroperitoneal LN
Colon, SB, RLQ, mesentery LN
Native kidney, retroperitoneal LN,
left calf skin
Lung
SB, mesenteric LN
CNS
Liver

Monomorphic enteropathyassociated T-cell
Monomorphic DLBCL − NHL
Monomorphic DLBCL − NHL

EBV−

Monomorphic DLBCL − NHL
Monomorphic B-cell lymphoma
− NHL
Monomorphic DLBCL − NHL
Monomorphic DLBCL − NHL
Monomorphic DLBCL − NHL
Polymorphic B-cell lymphoma
− NHL
Monomorphic DLBCL − NHL

EBV−
EBV+

Monomorphic primary
cutaneous GDTCL − NHL
Polymorphic DLBCL − NHL
Monomorphic DLBCL − NHL
Monomorphic DLBCL − NHL
Monomorphic
DLBCL − NHL
Monomorphic hepatosplenic
GDTCL − NHL

EBV−

Left neck skin, lung, mediastinum,
LLQ mass, mesenteric LN*
LN in chest, abdomen, and pelvis;
bone marrow, skin
CNS
CNS
Liver
Left cervical neck LN
Liver, spleen, bone marrow,
mediastinal LN

EBV+
EBV−

EBV+
EBV−
EBV+
EBV+
EBV−

EBV+
EBV+
EBV−
EBV+
EBV−

CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; EBV−, Epstein-Barr virus negative; EBV+, Epstein-Barr virus positive;
GDTCL, gamma-delta T-cell lymphoma; LLQ, left lower quadrant; LN, lymph node; NHL, non-Hodgkin lymphoma; PTLD, posttransplant lymphoproliferative disorder;
RLQ, right lower quadrant; SB, small bowel; Tx, transplant.
* Concurrent renal cell carcinoma.

patients had purely extranodal involvement (CNS, liver, lungs)
(Table 2).
PTLD was of B-cell lineage in 13 patients. Histology was
monomorphic in 11 out of these 13 patients with B-cell PTLD.
Three patients had T-cell PTLD, out of which 2 patients had
GDTCL (hepatosplenic and primary cutaneous) and 1 had cytotoxic enteropathy-associated T-cell lymphoma. Fifteen patients
had non-Hodgkin lymphoma. PTLD was histologically EBV
positive in 50% of patients. One patient also developed concurrent renal-cell carcinoma with PTLD (Table 2).
Management

Antiproliferative agents and calcineurin inhibitors (CNIs) were
discontinued in all patients at diagnosis, and patients were
maintained on steroid monotherapy for the duration of PTLD
treatment. Fourteen patients were treated with chemotherapy
regimens alone, 1 patient received chemotherapy with radiation,
and 1 patient received radiation alone. For chemotherapy regimens, 7 patients received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), 2 patients
received rituximab monotherapy, 2 patients received high-dose
methotrexate, 1 patient received CHOP, 1 patient received
CHOEP (CHOP plus etoposide), 1 patient received rituximab
therapy with resection, 1 patient with T-cell PTLD received salvage therapy (gemcitabine, dexamethasone, carboplatin), and 1
patient with CNS PTLD received temozolomide (Table 3).

One patient with CNS, EBV negative−B-cell PTLD received
1 cycle of R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin) followed by 1 cycle of R-Hyper-CVAD (rituximab,
cyclophosphamide, vincristine, doxorubicin, dexamethasone)
followed by 8 cycles of high-dose methotrexate with complete
remission. This patient had a relapse of PTLD 3 years after initial treatment and was given 1 cycle of R-CHOP and dexamethasone without resolution. Another patient with multifocal, EBV
negative−T-cell PTLD was treated with 3 cycles of CHOEP
and 2 cycles of salvage therapy with complete remission. He
relapsed 4 months later and died shortly thereafter (Table 3).
Treatment was complicated by tumor lysis syndrome in 3
patients, sepsis in 3, BK viremia in 1, and pneumocystis pneumonia in 2. In patients who achieved complete remission, the immunosuppressive regimen was optimized. Although 4 patients were
maintained on steroid monotherapy, other patients were treated
with steroids in combination with everolimus or tacrolimus added.
Patient Outcomes

Acute renal dysfunction and graft survival. At the time of
PTLD diagnosis, before treatment, the eGFR was similar to the
baseline eGFR posttransplant in all patients. During treatment,
the eGFR dropped in 44% (7) of patients and was preserved in
56% (9). At the end of treatment, 31% (5) of patients had a
lower eGFR than their baseline, whereas 69% recovered their
renal function (Table 4, Fig 1).
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Table 3. Treatment and Patient Outcomes

Patient PTLD Treatment

Posttreatment
Immunosuppression

Acute Renal
Dysfunction
Postdiagnosis

PTLD Outcomes

Patient
Outcomes

Cause
of Death

−
Yes − dialysis
GC + EVL
No
GC + EVL (after
Yes
initial treatment)

No remission
Complete remission
Complete remission with
relapse 3 years later

Deceased CT
Surviving
Deceased CT (family
withdrew care)

GC + EVL
GC

Yes
No

Complete remission
Complete remission

Surviving
Surviving

No

Complete remission

Surviving

Yes − dialysis

Complete remission

6

Resection + Rituximab 1 £
R-CHOP: 8 cycles
R-DHAP: 1 cycle; R-Hyper-CVAD: 1
cycle (1B + 1A) and partial cycle 2B;
rituximab + HD-MTX: 8 cycles
Relapse 3 years later;
Dexamethasone + 1 cycle R-CHOP
R-CHOP: 6 cycles
Nephrectomy; R-CHOP: 6 cycles;
radiation: 20 cycles
R-CHOP: 6 cycles

7

R-CHOP: 6 cycles

GC + EVL (only
for 3 months)
GC + EVL

8

Whole brain radiation + levetiracetam

GC

Yes − dialysis

Complete remission

Deceased Infection (hospice
home care)
Deceased Infection

9
10
11
12

5 weeks of rituximab 4 £
R-CHOP: 1 cycle
EPOCH: 6 cycles
HD-MTX: 8 cycles + rituximab on cycles
3-6
4 weeks of rituximab £ 4
cycles + temozolomide £ 7 every 28day cycles
6 weeks of rituximab 4 £

GC + FK
−
−
GC

No
Yes
Yes
Yes

Complete remission
No remission
No remission
Ongoing treatment

Surviving
Deceased CT
Deceased CT
Surviving

−

No

No remission

Deceased CT (sepsis)

GC + EVL

No

Complete remission

−
GC

Yes
Yes − dialysis

No remission
Complete remission with
relapse 4 months later

Deceased Pyoderma
gangrenosum
Deceased CT (sepsis)
Deceased CT (sepsis)

1
2
3

4
5

13

14
15
16

CHOP: 1 cycle
CHOEP: 2 cycles; salvage therapy: 3
cycles

CHOEP, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisolone; CT, patient died during chemotherapy or as a result of chemotoxicity; CVAD, rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; EVL, everolimus; FK,
tacrolimus; GC, glucocorticoids; PTLD, posttransplant lymphoproliferative disorder; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; RDHAP, rituximab, dexamethasone, cytarabine, cisplatin; R-Hyper- HD-MTX, high-dose methotrexate.

However, 62.5% (10) of patients had an episode of acute
renal dysfunction after PTLD diagnosis. Out of these 10
patients, 40% (4 of 10) developed dialysis-dependent renal failure (Table 3). Four patients on dialysis had an eGFR of ≤40
mL/min/1.73 m2 before PTLD treatment and had a 100% mortality rate (Table 4, Fig 1). In the other 6 patients, acute renal
dysfunction resolved; however, 4 of these 6 patients eventually
died. Out of the 10 patients who died in our cohort, 6 patients
died with a functioning graft (Table 3).
Patient survival. Ten of 16 (62.5%) patients diagnosed with
PTLD died. The median time to death after the diagnosis of
PTLD was 6.5 months. Seventy percent (7 of 10) of patients
died of complications related to chemotherapy (infections) and
PTLD. The other remaining patients died of other causes unrelated to their PTLD diagnosis or treatment. We observed that
the average eGFR (pre, during, and posttreatment) was lower in
patients who eventually died of PTLD compared with patients
who survived (Table 4).
Mortality was 100% (3 of 3) in PTLD with T-cell involvement and 54% (7 of 13) in PTLD with B-cell involvement. All
patients with T-cell PTLD died within 12 months of diagnosis.

Mortality was 83% (5 of 6) in patients who received basiliximab induction and 55% (5 of 9) in patients who received rATG
induction; 1 patient who received both basiliximab and rATG
survived. Although patients with bone marrow involvement
had 100% (3 of 3) mortality, 78% (7 of 9) of patients with
lymph node involvement died. EBV-negative PTLD had a
higher mortality rate (87.5% [7 of 8]) than EBV-positive PTLD
(37.5% [3 of 8]).
PTLD Outcomes

Complete remission (CR) was achieved in 62.5% (10) of
patients, of which 50% (5 of 10) eventually died. In patients
with B-cell PTLD, 61.5% (8 of 13) achieved CR, and 1 patient
had relapse of disease. Of the 3 patients with T-cell PTLD, only
1 patient achieved complete remission but eventually had
relapse of disease. Three patients with EBV-negative PTLD
achieved CR, and 2 had relapse of disease. Five patients with
EBV-positive PTLD achieved CR. Of the 3 patients who presented with bone marrow involvement, only 1 had relapse of
disease. Of the 9 patients with lymph node involvement, 3
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Table 4. eGFR Before, During, and Posttreatment

Patient

Sex

Race

Age at
Diagnosis (y)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

M
F
M
F
M
F
F
M
F
F
M
F
F
M
M
M

W
W
H
W
A
W
A
A
H
W
W
A
A
W
W
A

66
58
64
45
67
39
44
56
55
72
67
67
88
70
55
43

Mean eGFR Before
treatment
(mL/min/1.73 m2)

Mean eGFR During
treatment
`(mL/min/1.73 m2)

Mean eGFR 6 weeks
Post-treatment
(mL/min/1.73 m2)

31
41
73
49
95
67
39
30
79
83
23
48
51
104
83
36

31
60
86
53
94
42
25
22
78
46
30
49
76
103
89
54

13*
43
76
53
97
74
11
13
77
32*
27
56
110*
75
89*
67

A, African American; eGFR, estimated glomerular ﬁltration rate; F, female; H, Hispanic; M, male; W, white.
* Patient died during treatment. This is the last eGFR that was reported.

achieved CR and 2 with T-cell PTLD had relapse of disease
(Table 3).
DISCUSSION

PTLD is a complication of renal transplantation primarily
related to immunosuppression. It has a myriad of manifestations. PTLD localizes commonly to the digestive tract, lymph
nodes, and the nervous system but can involve any site, such as
lungs [1,10] and skin [11]. In our data set, the gastrointestinal
tract and lymph nodes were the most common sites. We also

presented RTRs with PTLD that localized to less common sites,
such as the bone marrow, perinephric space, and native kidney.
The timing of PTLD development has a bimodal distribution;
patients can present with early or late onset PTLD. Early PTLD
(PTLD developing within 1 year posttransplant) has been
argued to be clinically and pathologically different from late
PTLD (PTLD developing after 1 year posttransplant) [13-15].
The relative risk of developing PTLD is the highest within the
ﬁrst year posttransplant and decreases during consecutive years
[1]. Early PTLD is characterized as being EBV positive, CD20
positive, is induced by over-immunosuppression, and

Fig 1. Estimated glomerular ﬁltration
rate (eGFR) before, during, and posttreatment. The median of the eGFRs
values listed in Table 4 are charted
with a standard deviation before, during, and after posttransplant lymphoproliferative disorder treatment.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on July 22, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

1524

PATIL, PRASHAR, PATEL ET AL

commonly involves the engrafted organ [15]. Late-onset PTLD
is similar to lymphomas that occur in nonimmunosuppressed
patients; it is rarely EBV induced, often disseminated with
lymph node enlargement, and is associated with poor prognosis
[13,14]. In our data, only 2 patients developed early PTLD; 1
patient was EBV positive and achieved complete remission,
and the other patient was EBV negative and died within a year
of PTLD diagnosis but had a T-cell lymphoma. Our data also
support previous sources in that late PTLD has a poor prognosis; 90% of deceased patients developed PTLD >1 year after
transplantation. When examining patient survival based on the
amount of time (in months) from transplantation to PTLD diagnosis, we observed that surviving patients developed PTLD at a
median of 80 months as opposed to patients who died (median
of 96.5 months). The reason for this observation is unclear. In a
study conducted by Ghobrial et al and in a separate study by
Khedmat and Taheri, there was no signiﬁcant difference in
overall survival between early and late PTLD groups [15,16].
However, the patient population in the Ghobrial et al study
included a variety of solid organ transplant patients, not solely
renal transplant recipients. Whether early vs late PTLD has any
implications on renal transplant recipient survival remains
unclear and requires further evaluation.
A modiﬁable risk factor for PTLD development is the induction immunosuppression that a patient receives at the time of
transplantation. Our patients received either rATG, a polyclonal
antibody, or basiliximab, an IL-2 receptor antagonist. Several
studies have proposed that rATG induction is associated with
an increased risk for developing PTLD as compared with basiliximab [17,18]. Other studies have demonstrated that polyclonal induction is not associated with a signiﬁcant increased
risk of PTLD development [19,20]. The effects of rATG on
PTLD development are not conclusive, but there does seem to
be a consensus that IL-2 receptor antagonists do not increase
the risk [5,18] or are associated with a comparatively smaller
risk for PTLD development [19]. Although we did not speciﬁcally look at the risk of PTLD development, in our data, patients
who received rATG induction were diagnosed with PTLD at a
median of 97 months compared with patients who received
basiliximab (median of 27 months). The PTLD EBV status and
the maintenance immunosuppression between patients who
received rATG vs basiliximab were similar.
A meta-analysis conducted by Liu et al [21] suggested no
signiﬁcant difference between basiliximab vs rATG induction in terms of patient death; however, this study did not
speciﬁcally examine transplant patients who had developed
PTLD. Consequently, there is little to no literature examining the direct effects of induction on mortality in patients
with renal PTLD. In our patient cohort, we observed a high
mortality rate with basiliximab induction (83%) as opposed
to rATG (55%) induction, with no difference in the number
of deceased patients who achieved complete remission or
relapsed between the groups. The direct impact of induction
is likely difﬁcult to isolate because of confounding variables
such as varying posttransplant immunosuppressants and
treatment regimens. However, because induction type is
modiﬁable, studying the effects of rATG and basiliximab on

PTLD patient mortality is merited to improve long-term
patient outcomes.
After transplantation, patients are treated with maintenance
immunosuppression often consisting of MMF, tacrolimus, and
prednisone to prevent acute rejection and loss of the renal allograft. In 2 separate articles, Caillard et al suggests that MMF
and Mechanistic Target of Rapamycin (mTOR) inhibitors are
associated with a lower risk of PTLD development as compared
with patients treated with tacrolimus [5,10], even when accounting for confounding factors (EBV status, age). Moreover, several other studies suggest that mTOR inhibitors may reduce the
risk of developing PTLD via an anti-inﬂammatory and antiproliferative pathway [22] and are effective in treating EBV-positive PTLD, especially when combined with a PI3K/Akt
inhibitor [23]. A retrospective study conducted by Sampaio et
al [24] also suggests that a combination of mTOR inhibitors
and tacrolimus in patients with EBV-negative PTLD is associated with an increased risk of PTLD, graft failure, and mortality.
Other studies also demonstrate an increased risk of developing
PTLD with tacrolimus than with cyclosporine [1,5]; further
comparison of the 2 CNIs is warranted, as they are often used
in standard immunosuppressive regimens. Although maintenance therapy is tailored to each patient, optimal combinations
of immunosuppressive agents should be identiﬁed to decrease
the risk of PTLD development. It may even possible that no single immunosuppressive agent or regimen is associated with an
increased risk of PTLD but rather the cumulative immunosuppression posttransplant that leads to lymphoproliferation [25].
PTLD is often linked to EBV; however, studies have demonstrated conﬂicting data on the impact of histologic EBV status
on PTLD prognosis and survival [10,26-29]. Studies suggest
that EBV-negative PTLD is associated with a longer time to
PTLD diagnosis (late PTLD) [27,29], monomorphic histology
[27], and a worse prognosis [29]. Other studies argue that EBV
status is not indicative of patient survival [26,28,30]. We
observed that EBV-negative PTLD had a mortality of 87.5%
and a longer median time (96.5 months) from transplantation to
PTLD diagnosis as compared with EBV-positive PTLD, which
had a mortality of 37.5% and a median time of 80 months.
EBV-negative PTLD is also more commonly seen in male
patients [10], a trend also seen in our data; we observed a 100%
mortality in male patients with EBV-negative PTLD vs 66%
mortality in female patients with EBV-negative PTLD. All
EBV-negative PTLD patients also presented with a monomorphic histology, supporting ﬁndings from previous references.
Interestingly, we also noted that the average eGFR (pre, during,
and posttreatment) was lower in patients with EBV-negative
PTLD as compared with EBV-positive PTLD.
T-cell PTLD is a rare outcome of renal transplantation and
often presents with a higher mortality than B-cell PTLD [31].
GDTCL, speciﬁcally, is characterized by the World Health
Organization into 2 distinct groups: primary cutaneous and hepatosplenic. Both GDTCLs present aggressively and are associated with a signiﬁcantly worse prognosis [32,33]. We presented
3 patients with aggressive T-cell PTLDs (1 primary cutaneous
GDTCL, 1 hepatosplenic GDTCL, and 1 cytotoxic enteropathy-associated T-cell lymphoma) that were resistant to
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conventional chemotherapy regimens (rituximab, CHOEP) and
had a 100% mortality rate within 12 months of diagnosis. Most
data on T-cell PTLD consist of case reports/series, and there
has yet to be an effective treatment regimen developed for this
disease. Resistance and a poor long-term survival outcome with
standard chemotherapy regimens have been cited throughout
the literature; 2 larger case series demonstrated a poor longterm survival outcome for hepatosplenic GDTCL when treated
with the standard CHOP regimen [34,35]. Treatment options
that suggest improved survival for hepatosplenic GDTCL consist of non-CHOP regimens (HyperCVAD [cyclophosphamide,
vincristine, doxorubicin, dexamethasone]) with alternating
methotrexate and cytarabine [35]), pentostatin [36], and autologous or allogenic stem cell transplant [37]. Case reports have
also demonstrated stem cell transplant as an effective potential
treatment option for primary cutaneous GDTCL [38,39]. Further exploration of early treatment options is required to address
this aggressive subtype of PTLD.
The goal of PTLD treatment is to achieve complete remission
while preserving graft function.
Serre et al [40] noted that an eGFR of ≤30 mL/min/1.73 m2
at the time of PTLD diagnosis and the absence of calcineurin
inhibition in maintenance immunosuppression were independent risk factors for allograft loss. Among our patients who had
an eGFR of ≤40 mL/min/1.73 m2 (2 of which had an eGFR
≤30 mL/min/1.73 m2) before treatment, 3 experienced allograft
loss and there was 100% mortality.
Treatment of PTLD is not standardized but often follows
international recommendations, which generally consist of
reducing or stopping all maintenance immunosuppressive
agents, except for prednisone, and initiating speciﬁc rituximab
and/or chemotherapy regimens for more severe presentations
[41]. Complete CNI withdrawal has been associated with worse
long-term renal graft function [42], whereas reduction in maintenance CNI agents has been suggested to improve renal graft
outcomes [40,43]. In our patients, antiproliferative agents and
CNIs were completely stopped after PTLD diagnosis; 37.5%
(6) of patients died with a functioning graft and 25% (4) of
patients required dialysis and died with a nonfunctioning graft.
Another case series also suggested potential beneﬁt in replacing
CNI agents with mTOR inhibitors instead of withdrawing all
immunosuppression [44].
Treatment options involve reducing immunosuppression in
conjunction with rituximab alone or in combination with other
chemotherapeutic agents. Rituximab monotherapy has been
demonstrated to be an effective and well-tolerated treatment for
PTLD, especially PTLD that is EBV positive and CD20 positive [12]. In our data, only 2 patients were treated with rituximab monotherapy. Both patients had PTLD presenting in the
liver; 1 patient had EBV-negative PTLD and died, whereas the
other patient was EBV positive and achieved complete remission, similar to previous reports. Moreover, Choquet et al [45]
used a PTLD prognostic-speciﬁc index (>60 years old, Eastern
Cooperative Oncology Group Performance Status 2-4, and elevated lactate dehydrogenase) to predict overall survival in low,
intermediate, and high-risk PTLD patients treated with solely
rituximab; 2-year survival rates were 88%, 55%, and 0%,
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respectively. Although rituximab monotherapy is effective in
low-risk patients, it may not be the optimal treatment option for
intermediate- and high-risk patients.
For patients in which rituximab fails, adjunct chemotherapy
can be initiated [46,47]. However, chemotherapy involves a
high toxicity [47,48] and is associated with an increased mortality when given alone as opposed to in combination with rituximab [49]. Elstrom et al [48] recommend reserving
chemotherapy-based treatment plans for patients in which
rituximab fails, or those who have EBV-negative disease. In
our data set, 60% (6) of patients died of treatment-related
complications.
Limitations

This was a descriptive analysis; we did not have adequate
number of patients to conduct a statistical analysis.

CONCLUSIONS

Our data demonstrate the varying manifestations of PTLD.
PTLD can arise in single or multiple sites and can occur at any
time after transplantation. PTLD has a myriad of presentations,
and clinicians should have a low index of suspicion for this
entity in immunocompromised posttransplant patients. Renal
transplant recipients with T-cell PTLD, PTLD involving the
bone marrow and lymph nodes, and EBV-negative PTLD have
a poor prognosis despite therapy.
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